Sinovac Biotech, Overview
Valuation check: SVA's ROE is 0.31%, below the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow0.31%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Sinovac Biotech, (SVA) currently reports a ROE of 0.31%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Sinovac Biotech,'s ROE history and peer comparisons.
Sinovac Biotech,'s ROE of 0.31% is lower than the Healthcare sector average of 21.67%. That is roughly 98.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Sinovac Biotech,'s current 0.31% should be judged against Healthcare norms (sector average: 21.67%) and against SVA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 0.31%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Sinovac Biotech,, and consider following SVA for alerts when major investors trade the stock.
Sinovac Biotech, is classified in the Healthcare sector. On ROE, it currently shows 0.31% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SVA with unrelated industries.
